TenX Keane
TenX Keane
TENK
NASDAQ
0.72
USD
-2.70%
About
Citius Oncology, Inc. is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products with a focus on oncology products. Its LYMPHIR (denileukin diftitox-cxdl) is approved by United States Food and Drug Administration for the treatment of adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma (a rare form of non-Hodgkin lymphoma) after at least one prior systemic therapy.
LYMPHIR is a specially engineered IL-2- diphtheria toxin fusion protein made using recombinant DNA technology. It works by targeting cells that have IL-2 receptors with a toxin derived from diphtheria bacteria. It directly kills tumor cells by binding to the IL-2 receptors and internalizing the diphtheria toxin directly into the tumor cells, causing them to die.
It boosts the body's immune response by reducing the number of regulatory T-cells (Tregs) that suppress the immune system, thereby enhancing the body's ability to fight the tumor..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 189.0K |
| Three Month Average Volume | 3.4M |
| High Low | |
| Fifty-Two Week High | 49 USD |
| Fifty-Two Week Low | 1.53 USD |
| Fifty-Two Week High Date | 06 Aug 2024 |
| Fifty-Two Week Low Date | 29 Aug 2024 |
| Price and Volume | |
| Current Price | 1.77 USD |
| Beta | -100,000 |
| Relative Price Change | |
| Four Week Relative Price Change | -86.39% |
| Thirteen Week Relative Price Change | -85.45% |
| Twenty-Six Week Relative Price Change | -85.38% |
| Fifty-Two Week Relative Price Change | -86.81% |
| Year-to-Date Relative Price Change | -86.34% |
| Price Change | |
| One Day Price Change | 0.00% |
| Thirteen Week Price Change | -84.43% |
| Twenty-Six Week Price Change | -83.92% |
| Five Day Price Change | -5.35% |
| Fifty-Two Week Price Change | -83.47% |
| Year-to-Date Price Change | -83.82% |
| Month-to-Date Price Change | -83.60% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 7.89373 USD |
| Book Value Per Share (Most Recent Quarter) | 6.93103 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 7.89373 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 6.93103 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -0.16739 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0 USD |
| Revenue Per Share (Trailing Twelve Months) | 0 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | 0.27037 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | 0.24196 USD |
| Normalized (Last Fiscal Year) | 0.27037 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | 0.27037 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | 0.24196 USD |
| Including Extraordinary Items (Last Fiscal Year) | 0.27037 USD |
| Including Extraordinary Items (Trailing Twelve Months) | 0.24196 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 0.00366 USD |
| Cash Per Share (Most Recent Quarter) | 4.0E-5 USD |
| Cash Flow Per Share (Last Fiscal Year) | 0.27037 USD |
| Cash Flow Per Share (Trailing Twelve Months) | 0.24558 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -0.11304 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -100,000 |
| Cash Flow Revenue (Trailing Twelve Months) | -100,000 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -99,999.99% |
| Pretax Margin (Last Fiscal Year) | -99,999.99% |
| Pretax Margin (5 Year) | -99,999.99% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -99,999.99% |
| Operating Margin (Trailing Twelve Months) | -99,999.99% |
| Operating Margin (5 Year) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -99,999.99% |
| Net Profit Margin (Trailing Twelve Months) | -99,999.99% |
| Net Profit Margin (5 Year) | -99,999.99% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -99,999.99% |
| Tangible Book Value (5 Year) | -99,999.99% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -99,999.99% |
| Revenue Growth (3 Year) | -99,999.99% |
| Revenue Change (Trailing Twelve Months) | -99,999.99% |
| Revenue Per Share Growth | -99,999.99% |
| Revenue Growth (5 Year) | -99,999.99% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -99,999.99% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | -44.49% |
| EPS Change (Trailing Twelve Months) | 35.59% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 2 |
| Price to Tangible Book (Most Recent Quarter) | 3 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | 1.7M |
| Net Debt (Last Fiscal Year) | 1.3M |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | -100,000 |
| Price to Sales (Trailing Twelve Months) | -100,000 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | 7 |
| PE Normalized (Last Fiscal Year) | 7 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | 47 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | 7 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 0 |
| Price to Book (Most Recent Quarter) | 0 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 0 |
| Long Term Debt to Equity (Most Recent Quarter) | 0 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | 0.00% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | 53 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | 66 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 0 |
| Current Ratio (Most Recent Quarter) | 0 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -601,300 |
| Free Cash Flow (Trailing Twelve Months) | -890,040 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 2 |
| Total Debt to Equity (Most Recent Quarter) | 4 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | 3.44% |
| Return on Assets (Trailing Twelve Months) | 3.25% |
| Return on Assets (5 Year) | -99,999.99% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | 3.49% |
| Return on Equity (Trailing Twelve Months) | 3.35% |
| Return on Equity (5 Year) | -99,999.99% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | 3.49% |
| Return on Investment (Trailing Twelve Months) | 3.35% |
| Return on Investment (5 Year) | -99,999.99% |